Design Therapeutics (DSGN) Share-based Compensation (2020 - 2026)

Design Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $3.9 million in Q2 2026.

• Share-based Compensation for Q2 2026 came in at $3.9 million, down 2.96% year-over-year; the trailing twelve-month figure through Jun 2026 was $14.8 million (up 4.98% YoY), and the FY2025 annual result was $20.7 million, up 21.05% from the prior year.
• Share-based Compensation retreated to $3.9 million in Q2 2026, from $3.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.0 million in Q2 2025 and troughed at $2.4 million in Q1 2022.
• A 5-year average of $3.3 million and a median of $3.4 million in 2023 frame the typical range for Share-based Compensation.
• The widest annual swing landed in 2022, when Share-based Compensation jumped 264.76%; it then declined 11.44% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $3.1 million in 2022, then dropped by 11.44% to $2.7 million in 2023, then climbed by 27.42% to $3.5 million in 2024, then retreated by 1.04% to $3.4 million in 2025, then gained by 12.58% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $3.9 million in Q2 2026, $3.9 million in Q1 2026, and $3.4 million in Q4 2025.